Safe and effective medicines for all: is personalized medicine the answer?

References

• DiMasi JA, Feldman L, Seckler A et al. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther.87(3), 272–277 (2010).
   PubMed Web of Science ®Google Scholar
• Davies EC, Green CF, Taylor S et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE4(2), e4439 (2009).
   PubMed Web of Science ®Google Scholar
• Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin. Pharmacol. Ther.81(6), 807–816 (2007).
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science286(5439), 487–491 (1999).
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med.57, 119–137 (2006).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations – ready for clinical practice? Nat. Rev. Drug. Discov.4(8), 639–647 (2005).
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature429(6990), 464–468 (2004).
   PubMed Web of Science ®Google Scholar
• Abrahams E, Ginsburg GS, Silver M. The Personalized Medicine Coalition: goals and strategies. Am. J. Pharmacogenomics5(6), 345–355 (2005).
   Google Scholar
• Abrahams E. Latest updates & news from the Personalized Medicine Coalition. Pers. Med.6(5) 479–480 (2009).
   Google Scholar
• Bönicke R, Reif W. Enzymatische inaktivierung von isonikotinsäurehydrazid in humanen und tierischen organismen. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol.220(4), 321–323 (1953).
   PubMedGoogle Scholar
• Donald PR, Parkin DP, Seifart HI et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur. J. Clin. Pharmacol.63(7), 633–639 (2007).
   PubMed Web of Science ®Google Scholar
• Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics11(5), 607–611 (2010).
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim SH, Bahn JW et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics10(11), 1767–1779 (2009).
   PubMed Web of Science ®Google Scholar
• Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy29(12), 1468–1481 (2009).
   PubMed Web of Science ®Google Scholar
• Ormerod LP. The evidence based treatment of tuberculosis: where and why are we failing? Thorax63(5), 388–390 (2008).
   Google Scholar
• Bertilsson L, Dahl ML, Dalen P et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol.53(2), 111–122 (2002).
   PubMed Web of Science ®Google Scholar
• Brosen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther.40(5), 543–549 (1986).
   PubMed Web of Science ®Google Scholar
• Brosen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Ther.49(6), 609–617 (1991).
   PubMed Web of Science ®Google Scholar
• Ghahramani P, Ellis SW, Lennard MS et al. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br. J. Clin. Pharmacol.43(2), 137–144 (1997).
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J. Clin. Pharmacol.39(6), 567–577 (1999).
   PubMed Web of Science ®Google Scholar
• Rau T, Heide R, Bergmann K et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics12(6), 465–472 (2002).
   PubMedGoogle Scholar
• Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin. Pharmacol. Ther.81(6), 899–902 (2007).
   PubMed Web of Science ®Google Scholar
• Laika B, Leucht S, Heres S et al. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost–effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J.9(6), 395–403 (2009).
   PubMed Web of Science ®Google Scholar
• Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin. Pharmacol. Ther.88(3), 354–349 (2009).
   Google Scholar
• Alfaro CL, Lam YW, Simpson J et al. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J. Clin. Psychopharmacol.19(2), 155–163 (1999).
   PubMed Web of Science ®Google Scholar
• Crewe HK, Lennard MS, Tucker GT et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol.34(3), 262–265 (1992).
   PubMed Web of Science ®Google Scholar
• Spigset O, Hedenmalm K, Dahl ML et al. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr. Scand.96(5), 379–384 (1997).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Brosen K, Dahl ML et al.CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand.104(3), 173–192 (2001).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Seeringer A, Viviani R. Pharmacogenetics in psychiatry – a useful clinical tool or wishful thinking for the future? Curr. Pharm. Des.16(2), 136–144 (2010).
   PubMed Web of Science ®Google Scholar
• Serretti A, Chiesa A, Calati R et al. Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. Int. Clin. Psychopharmacol.24(1), 1–18 (2009).
   PubMed Web of Science ®Google Scholar
• Sachse C, Brockmoller J, Bauer S et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet.60(2), 284–295 (1997).
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Kirchheiner J, Schmider J et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharmacol. Ther.72(4), 438–452 (2002).
   PubMed Web of Science ®Google Scholar
• Scordo MG, Spina E, Romeo P et al.CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur. J. Clin. Pharmacol.56(9–10), 679–683 (2000).
   PubMed Web of Science ®Google Scholar
• Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin. Pharmacokinet.41(7), 453–470 (2002).
   PubMed Web of Science ®Google Scholar
• Ferket BS, Colkesen EB, Visser JJ et al. Systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check? Arch. Intern. Med.170(1), 27–40 (2010).
   Google Scholar
• Samani NJ, Deloukas P, Erdmann J et al. Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler. Thromb. Vasc. Biol.29(5), 774–780 (2009).
   Google Scholar
• Lau YY, Huang Y, Frassetto L et al. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther.81(2), 194–204 (2007).
   PubMed Web of Science ®Google Scholar
• Mwinyi J, Johne A, Bauer S et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther.75(5), 415–421 (2004).
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics14(7), 429–440 (2004).
   PubMedGoogle Scholar
• Couvert P, Giral P, Dejager S et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics9(9), 1217–1227 (2008).
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med.359(8), 789–799 (2008).
   PubMed Web of Science ®Google Scholar
• Giessmann T, Modess C, Hecker U et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin. Pharmacol. Ther.75(3), 213–222 (2004).
   PubMed Web of Science ®Google Scholar
• Wuttke H, Rau T, Heide R et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin. Pharmacol. Ther.72(4), 429–437 (2002).
   PubMed Web of Science ®Google Scholar
• Fux R, Morike K, Prohmer AM et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin. Pharmacol. Ther.78(4), 378–387 (2005).
   PubMed Web of Science ®Google Scholar
• Clark DW, Morgan AK, Waal-Manning H. Adverse effects from metoprolol are not generally associated with oxidation status. Br. J. Clin. Pharmacol.18(6), 965–967 (1984).
   PubMed Web of Science ®Google Scholar
• Zineh I, Beitelshees AL, Gaedigk A et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin. Pharmacol. Ther.76(6), 536–544 (2004).
   PubMed Web of Science ®Google Scholar
• Rau T, Wuttke H, Michels LM et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin. Pharmacol. Ther.85(3), 269–272 (2009).
   PubMed Web of Science ®Google Scholar
• Hein L. Physiological significance of β-adrenergic receptor polymorphisms: in-vivo or in-vitro veritas? Pharmacogenetics11(3), 187–189 (2001).
   Google Scholar
• Leineweber K, Buscher R, Bruck H et al. β-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol.369(1), 1–22 (2004).
   PubMed Web of Science ®Google Scholar
• Brodde OE. β-adrenoceptor blocker treatment and the cardiac β-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch. Pharmacol.374(5–6), 361–372 (2007).
   PubMed Web of Science ®Google Scholar
• Liu J, Liu ZQ, Tan ZR et al. Gly389Arg polymorphism of β1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin. Pharmacol. Ther.74(4), 372–379 (2003).
   PubMed Web of Science ®Google Scholar
• White HL, De Boer RA, Maqbool A et al. An evaluation of the β1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur. J. Heart Fail.5(4), 463–468 (2003).
   PubMed Web of Science ®Google Scholar
• Beitelshees AL, Zineh I, Yarandi HN et al. Influence of phenotype and pharmacokinetics on β-blocker drug target pharmacogenetics. Pharmacogenomics J.6(3), 174–178 (2006).
   PubMed Web of Science ®Google Scholar
• Brodde OE, Leineweber K. β2-adrenoceptor gene polymorphisms. Pharmacogenet. Genomics15(5), 267–275 (2005).
   PubMed Web of Science ®Google Scholar
• Lanfear DE, Jones PG, Marsh S et al. β2-adrenergic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome. JAMA294(12), 1526–1533 (2005).
   PubMed Web of Science ®Google Scholar
• Aithal GP, Day CP, Kesteven PJ et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet353(9154), 717–719 (1999).
   PubMed Web of Science ®Google Scholar
• Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther.83(3), 460–470 (2008).
   PubMed Web of Science ®Google Scholar
• D’Andrea G, D’Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood105(2), 645–649 (2005).
   PubMed Web of Science ®Google Scholar
• Yuan HY, Chen JJ, Lee MT et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet.14(13), 1745–1751 (2005).
   PubMed Web of Science ®Google Scholar
• Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360(8), 753–764 (2009).
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Hong SJ et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther.84(2), 236–242 (2008).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360(4), 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA301(9), 937–944 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation119(19), 2553–2560 (2009).
   PubMed Web of Science ®Google Scholar
• Gerr H, Zimmermann M, Schrappe M et al. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br. J. Haematol.149(1), 84–92 (2010).
   PubMed Web of Science ®Google Scholar
• Moricke A, Zimmermann M, Reiter A et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia24(2), 265–284 (2010).
   PubMed Web of Science ®Google Scholar
• Muller MC, Cross NC, Erben P et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia23(11), 1957–1963 (2009).
   PubMed Web of Science ®Google Scholar
• Nanda R. Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. Rev. Recent Clin. Trials2(2), 111–116 (2007).
   Google Scholar
• Hoskins JM, Goldberg RM, Qu P et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst.99(17), 1290–1295 (2007).
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Fischer C, Brockmeier D et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German–Caucasians and identification of novel TPMT variants. Pharmacogenetics14(7), 407–417 (2004).
   PubMedGoogle Scholar
• Stanulla M, Schaeffeler E, Flohr T et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA293(12), 1485–1489 (2005).
   PubMed Web of Science ®Google Scholar
• Wu X, Hawse JR, Subramaniam M et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor α for degradation in breast cancer cells. Cancer Res.69(5), 1722–1727 (2009).
   PubMed Web of Science ®Google Scholar
• Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat.101(1), 113–121 (2007).
   PubMed Web of Science ®Google Scholar
• Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA302(13), 1429–1436 (2009).
   PubMed Web of Science ®Google Scholar
• Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol.25(33), 5187–5193 (2007).
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer9(8), 576–586 (2009).
   PubMed Web of Science ®Google Scholar
• Pirmohamed M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J.8(1), E20–E26 (2006).
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G et al.HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358(6), 568–579 (2008).
   PubMed Web of Science ®Google Scholar
• Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin. Liver Dis.29(4), 400–411 (2009).
   PubMed Web of Science ®Google Scholar
• Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol. Ther.25(10), 1135–1151 (2007).
   PubMed Web of Science ®Google Scholar
• Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr. Opin. Gastroenterol.24(3), 287–297 (2008).
   PubMed Web of Science ®Google Scholar
• Meadows M. Serious liver injury. Leading reason for drug removals, restrictions. FDA Consum.35(3), 8–9 (2001).
   Google Scholar
• Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb. Exp. Pharmacol.196, 407–418 (2010).
   PubMedGoogle Scholar
• Kindmark A, Jawaid A, Harbron CG et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J.8(3), 186–195 (2008).
   PubMed Web of Science ®Google Scholar
• Daly AK, Aithal GP, Leathart JB et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology132(1), 272–281 (2007).
   PubMed Web of Science ®Google Scholar
• Cascorbi I. Genetic basis of toxic reactions to drugs and chemicals. Toxicol. Lett.162(1), 16–28 (2006).
   PubMed Web of Science ®Google Scholar
• Dawood S, Leyland-Jones B. Pharmacology and pharmacogenetics of chemotherapeutic agents. Cancer Invest.27(5), 482–488 (2009).
   PubMed Web of Science ®Google Scholar
• Ikediobi ON. Somatic pharmacogenomics in cancer. Pharmacogenomics J.8(5), 305–314 (2008).
   PubMed Web of Science ®Google Scholar
• Parkinson DR, Ziegler J. Educating for personalized medicine: a perspective from oncology. Clin. Pharmacol. Ther.86(1), 23–25 (2009).
   Google Scholar
• Yan L, Beckman RA. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques39(4), 565–568 (2005).
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Schrauder A, Raff T et al. Standardized MRD quantification in European ALL trials. Presented at: Proceedings of the Second International Symposium on MRD Assessment. Kiel, Germany, 18–20 September 2008.
   Google Scholar
• Martin-Subero JI, Ammerpohl O, Bibikova M et al. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS ONE4(9), e6986 (2009).
   PubMed Web of Science ®Google Scholar
• Serretti A, Calati R, Massat I et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int. Clin. Psychopharmacol.24(5), 250–256 (2009).
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Kirchheiner J, Meisel C et al. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics1(2), 125–151 (2000).
   PubMedGoogle Scholar
• Jakovljevic M. New generation vs. first generation antipsychotics debate: pragmatic clinical trials and practice-based evidence. Psychiatr. Danub.21(4), 446–452 (2009).
   Google Scholar
• Arnett DK, Claas SA, Lynch AI. Has pharmacogenetics brought us closer to ‘personalized medicine’ for initial drug treatment of hypertension? Curr. Opin. Cardiol.24(4), 333–339 (2009).
   PubMed Web of Science ®Google Scholar
• Fleeman N, Dickson R. Providing patients with information on pharmacogenetic testing. Nurs. Stand.23(21), 46–48 (2009).
   Google Scholar
• Collins CD, Purohit S, Podolsky RH et al. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul. Pharmacol.45(5), 258–267 (2006).
   PubMed Web of Science ®Google Scholar
• Frueh FW. Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice. Pharmacogenomics11(5), 657–660 (2010).
   Google Scholar
• Frueh FW, Amur S, Mummaneni P et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy28(8), 992–998 (2008).
   PubMed Web of Science ®Google Scholar
• Gomez A, Ingelman-Sundberg M. Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. Pharmacogenomics10(7), 1067–1076 (2009).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Gomez A. The past, present and future of pharmacoepigenomics. Pharmacogenomics11(5), 625–627 (2010).
   PubMed Web of Science ®Google Scholar